SEK 0.01
(-3.23%)
Year | Eps | Eps Growth |
---|---|---|
2023 | -0.15 SEK | 77.94% |
2022 | -0.68 SEK | -50.0% |
2021 | -0.22 SEK | -273.51% |
2020 | -0.06 SEK | 0.0% |
Year | Eps | Eps Growth |
---|---|---|
2024 Q1 | -0.08 SEK | 0.0% |
2024 Q2 | -0.02 SEK | 75.0% |
2024 Q3 | -0.01 SEK | 62.0% |
2023 FY | - SEK | 54.55% |
2023 Q4 | - SEK | 100.0% |
2023 Q2 | -0.08 SEK | 27.27% |
2023 Q1 | -0.11 SEK | 0.0% |
2023 Q3 | -0.04 SEK | 51.63% |
2022 Q4 | -0.08 SEK | 69.92% |
2022 Q3 | -0.26 SEK | 23.53% |
2022 Q2 | -0.34 SEK | -41.67% |
2022 Q1 | -0.24 SEK | -197.03% |
2022 FY | - SEK | -50.0% |
2021 Q1 | -0.05 SEK | 0.0% |
2021 Q4 | -0.08 SEK | 32.67% |
2021 FY | - SEK | -273.51% |
2021 Q3 | -0.12 SEK | 7.69% |
2021 Q2 | -0.13 SEK | -141.19% |
2020 Q3 | -0.03 SEK | -212.77% |
2020 FY | - SEK | 0.0% |
2020 Q2 | -0.01 SEK | 0.0% |
2020 Q4 | - SEK | 100.0% |
Name | Eps | Eps Difference |
---|---|---|
AroCell AB (publ) | -0.26 SEK | 42.308% |
Devyser Diagnostics AB (publ) | -3.31 SEK | 95.468% |
Immunovia AB (publ) | -7.38 SEK | 97.967% |
Prostatype Genomics AB (publ) | -0.24 SEK | 37.5% |
SenzaGen AB | -0.91 SEK | 83.516% |